Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study
Abstract Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a new cancer drug to market. However, many development efforts are aimed at extending the label of already approved drugs. Herein, we...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-42213-y |